Cargando…

Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil

INTRODUCTION: In lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) patients, prostate volume (PV) at baseline affects the improvement of International Prostate Symptom Score voiding symptoms (IPSS-VS) by naftopidil (NAF), but not total IPSS (IPSS-TS). To predict th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanuma, Yasushi, Tanaka, Yoshinori, Okamoto, Tomoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343274/ https://www.ncbi.nlm.nih.gov/pubmed/34421268 http://dx.doi.org/10.4103/UA.UA_93_20

Ejemplares similares

Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
por: Tanuma, Yasushi, et al.
Publicado: (2016)

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study
por: Tanuma, Yasushi, et al.
Publicado: (2017)

Crystal structures, absolute configurations and molecular docking studies of naftopidil enantiomers as α(1D)-adrenoceptor antagonists
por: Xu, Wei, et al.
Publicado: (2017)

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
por: Tanaka, Nobumichi, et al.
Publicado: (2014)

The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers
por: Batty, Mallory, et al.
Publicado: (2016)

Drug Repositioning of the α(1)-Adrenergic Receptor Antagonist Naftopidil: A Potential New Anti-Cancer Drug?
por: Florent, Romane, et al.
Publicado: (2020)

A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement
por: Perumal, Chenthil, et al.
Publicado: (2015)

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
por: Masumori, Naoya
Publicado: (2011)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2020)

The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G.W., et al.
Publicado: (2022)

Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer
por: Mihalopoulos, Meredith, et al.
Publicado: (2020)

The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum
por: Wuest, Melinda, et al.
Publicado: (2011)

Add-on Therapy With the α-Blockers Tamsulosin and Naftopidil Improves Voiding Function by Enhancing Neuronal Activity in Prostatic Hyperplasia Rats
por: Ko, Il-Gyu, et al.
Publicado: (2018)

Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study
por: Chung, Mun Su, et al.
Publicado: (2017)

"Ejaculatory disorders and α(1)-adrenoceptor antagonists therapy: clinical and experimental researches"
por: Grasso, Marco, et al.
Publicado: (2006)

Effects of α-Adrenoceptor Antagonists on ABCG2/BCRP-Mediated Resistance and Transport
por: Takara, Kohji, et al.
Publicado: (2012)

Use of α1‐adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease
por: Latvala, Laura, et al.
Publicado: (2022)

The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2021)

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014)

Chemically Homogenous Compounds with Antagonistic Properties at All α(1)-Adrenoceptor Subtypes but not β(1)-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats
por: Pytka, Karolina, et al.
Publicado: (2016)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Tanaka, Yoshinori, et al.
Publicado: (2017)

Search for new α1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Khurana, Naval, et al.
Publicado: (2007)

The cytotoxicity of the α1-adrenoceptor antagonist prazosin is linked to an endocytotic mechanism equivalent to transport-P
por: Fuchs, Robert, et al.
Publicado: (2015)

The signaling and selectivity of α‐adrenoceptor agonists for the human α2A, α2B and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2022)

Quinazoline-based α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-β signalling and IκBα induction
por: Partin, J V, et al.
Publicado: (2003)

Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat
por: Shimizu, Shogo, et al.
Publicado: (2015)

β(1) Adrenoceptor antagonistic effects of the supposedly selective β(2) adrenoceptor antagonist ICI 118,551 on the positive inotropic effect of adrenaline in murine hearts
por: Pecha, Simon, et al.
Publicado: (2015)

Naftopidil reduced the proliferation of lung fibroblasts and bleomycin‐induced lung fibrosis in mice
por: Urushiyama, Hirokazu, et al.
Publicado: (2019)

A Novel Structural Framework for α(1A/D)-Adrenoceptor Selective Antagonists Identified Using Subtype Selective Pharmacophores
por: Stoddart, Emily S., et al.
Publicado: (2011)

Efficacy of Naftopidil as a Medical Expulsive Therapy in Japanese Men With Ureteral Stones: A Prospective Randomized Controlled Study
por: Ohgaki, Kenji
Publicado: (2019)

Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan
por: Masumori, Naoya, et al.
Publicado: (2016)

X-ray Crystallography, DFT Calculations and Molecular Docking of Indole-Arylpiperazine Derivatives as α(1A)-Adrenoceptor Antagonists
por: Xu, Wei, et al.
Publicado: (2015)

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019)

Changes in energy metabolism, and levels of stress-related hormones and electrolytes in horses after intravenous administration of romifidine and the peripheral α-2 adrenoceptor antagonist vatinoxan
por: Pakkanen, Soile Anja Eliisa, et al.
Publicado: (2018)

Effects of Spinal and Peripheral Injection of α1A or α1D Adrenoceptor Antagonists on Bladder Activity in Rat Models with or without Bladder Outlet Obstruction
por: Kim, Jae Heon, et al.
Publicado: (2011)

Randomized Controlled Trial to Compare the Safety and Efficacy of Naftopidil and Tamsulosin as Medical Expulsive Therapy in Combination With Prednisolone for Distal Ureteral Stones
por: Kumar, Santosh, et al.
Publicado: (2013)

Novel selective β(1)-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease
por: Baker, Jillian G., et al.
Publicado: (2017)

Effects of the α(1)-adrenoceptor agonist phenylephrine on SART stress-induced orthostatic hypotension in rats
por: Funakami, Yoshinori, et al.
Publicado: (2010)

Effect of α1D-adrenoceptor blocker for the reduction of ureteral contractions
por: Hong, Seong Hwi, et al.
Publicado: (2023)

The presence of β(2)-adrenoceptors sensitizes α(2A)-adrenoceptors to desensitization after chronic epinephrine treatment
por: Bawa-Khalfe, Tasneem, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_fr18a58us9an7p3t3umo0lvcuo